Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 495305, 10 pages
http://dx.doi.org/10.1155/2015/495305
Research Article

DNA Damage and Inhibition of Akt Pathway in MCF-7 Cells and Ehrlich Tumor in Mice Treated with 1,4-Naphthoquinones in Combination with Ascorbate

1Laboratório de Bioquímica Experimental, Departamento de Bioquímica, Universidade Federal de Santa Catarina, Florianópolis, Brazil
2Programa de Pós-Graduação em Ciências da Saúde da Universidade do Sul de Santa Catarina (UNISUL), SC, Brazil
3Departamento de Ciencias Químicas y Farmacéuticas, Universidad Arturo Prat, 2120 Avenida Arturo Prat, Iquique, Chile
4Toxicology and Cancer Biology Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, 73 Avenue E. Mounier, GTOX 7309, 1200 Brussels, Belgium

Received 29 November 2014; Revised 19 January 2015; Accepted 19 January 2015

Academic Editor: Ryuichi Morishita

Copyright © 2015 Fabiana Ourique et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Gottesman, “Mechanisms of cancer drug resistance,” Annual Review of Medicine, vol. 53, pp. 615–627, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. M. S. Farias, C. T. Pich, M. R. Kviecinski et al., “Substituted 3-acyl-2-phenylamino-1,4-naphthoquinones intercalate into DNA and cause genotoxicity through the increased generation of reactive oxygen species culminating in cell death,” Molecular Medicine Reports, vol. 10, no. 1, pp. 405–410, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. K. B. Felipe, J. Benites, C. Glorieux et al., “Antiproliferative effects of phenylaminonaphthoquinones are increased by ascorbate and associated with the appearance of a senescent phenotype in human bladder cancer cells,” Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 573–578, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. R. Kviecinski, R. C. Pedrosa, K. B. Felipe et al., “Inhibition of cell proliferation and migration by oxidative stress from ascorbate-driven juglone redox cycling in human bladder-derived T24 cells,” Biochemical and Biophysical Research Communications, vol. 421, no. 2, pp. 268–273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. F. Thorn, C. Oshiro, S. Marsh et al., “Doxorubicin pathways: pharmacodynamics and adverse effects,” Pharmacogenetics and Genomics, vol. 21, no. 7, pp. 440–446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Bischoff and S. Hoffman, “DNA-binding of drugs used in medicinal therapies,” Current Medicinal Chemistry, vol. 9, no. 3, pp. 321–348, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Palchaudhuri and P. J. Hergenrother, “DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action,” Current Opinion in Biotechnology, vol. 18, no. 6, pp. 497–503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. S. Shahabuddin, M. Gopal, and S. C. Raghavan, “Intercalating and antitumor activity of 4 oxopyrimido[4′,5′:4,5]thieno(2,3-b) quinoline-4(3H)-one,” Journal of Cancer Molecules, vol. 3, pp. 139–146, 2007. View at Google Scholar
  9. Q. Chen, M. G. Espey, M. C. Krishna et al., “Pharamacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissuse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13604–13609, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Du, J. J. Cullen, and G. R. Buettner, “Ascorbic acid: chemistry, biology and the treatment of cancer,” Biochimica et Biophysica Acta, vol. 1826, no. 2, pp. 443–457, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. G. Espey, P. Chen, B. Chalmers et al., “Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer,” Free Radical Biology and Medicine, vol. 50, no. 11, pp. 1610–1619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Verrax, R. Beck, N. Dejeans et al., “Redox-active quinones and ascorbate: an innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress,” Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 2, pp. 213–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Benites, J. A. Valderrama, K. Bettega, R. C. Pedrosa, P. B. Calderon, and J. Verrax, “Biological evaluation of donor-acceptor aminonaphthoquinones as antitumor agents,” European Journal of Medicinal Chemistry, vol. 45, no. 12, pp. 6052–6057, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. V. C. da Silveira, H. Benezra, J. S. Luz, R. C. Georg, C. C. Oliveira, and A. M. D. C. Ferreira, “Binding of oxindole-Schiff base copper(II) complexes to DNA and its modulation by the ligand,” Journal of Inorganic Biochemistry, vol. 105, no. 12, pp. 1692–1703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Jun, W. Bochu, and Z. Liancai, “Hydrolytic cleavage of DNA by quercetin manganese(II) complexes,” Colloids and Surfaces B: Biointerfaces, vol. 55, no. 2, pp. 149–152, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. N. P. Singh, M. T. McCoy, R. R. Tice, and E. L. Schneider, “A simple technique for quantitation of low levels of DNA damage in individual cells,” Experimental Cell Research, vol. 175, no. 1, pp. 184–191, 1988. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Yuan, R. Adamski, and J. Chen, “Focus on histone variant H2AX: to be or not to be,” FEBS Letters, vol. 584, no. 17, pp. 3717–3724, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. T. T. Paull, E. P. Rogakou, V. Yamazaki, C. U. Kirchgessner, M. Gellert, and W. M. Bonner, “A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage,” Current Biology, vol. 10, no. 15, pp. 886–895, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Lopez, A. Arumugam, R. Joseph et al., “Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGF1R signaling and activation of AKT/mTOR,” PLoS ONE, vol. 8, no. 11, Article ID e79708, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. M. Ross, T. J. McMillan, P. Wilcox, and A. R. Collins, “The single cell microgel electrophoresis assay (comet assay): technical aspects and applications. Report on the 5th LH Gray Trust Workshop, Institute of Cancer Research, 1994,” Mutation Research, vol. 337, no. 1, pp. 57–60, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at Publisher · View at Google Scholar · View at Scopus
  22. N. A. P. Franken, H. M. Rodermond, J. Stap, J. Haveman, and C. van Bree, “Clonogenic assay of cells in vitro,” Nature Protocols, vol. 1, no. 5, pp. 2315–2319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Glorieux, N. Dejeans, B. Sid, R. Beck, P. B. Calderon, and J. Verrax, “Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy,” Biochemical Pharmacology, vol. 82, no. 10, pp. 1384–1390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. R. Kviecinski, P. Benelli, K. B. Felipe et al., “SFE from Bidens pilosa Linné to obtain extracts rich in cytotoxic polyacetylenes with antitumor activity,” Journal of Supercritical Fluids, vol. 56, no. 3, pp. 243–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. E. L. Kaplan and P. Meier, “Nonparametric estimation from incomplete observations,” Journal of the American Statistical Association, vol. 53, pp. 457–481, 1958. View at Publisher · View at Google Scholar · View at MathSciNet
  26. R. P. Bird and H. H. Draper, “Comparative studies on different methods of malonaldehyde determination,” Methods in Enzymology, vol. 105, pp. 299–305, 1984. View at Publisher · View at Google Scholar · View at Scopus
  27. V. G. S. Box, “The intercalation of DNA double helices with doxorubicin and nagalomycin,” Journal of Molecular Graphics and Modelling, vol. 26, no. 1, pp. 14–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. Q. Jiang, N. Xiao, P. Shi, Y. Zhu, and Z. Guo, “Design of artificial metallonucleases with oxidative mechanism,” Coordination Chemistry Reviews, vol. 251, no. 15-16, pp. 1951–1972, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. U. Rehman, M. Tahir, A. Q. Khan et al., “D-limonene suppresses doxorubicin-induced oxidative stress and inflammation via repression of COX-2, iNOS, and NFκB in kidneys of Wistar rats,” Experimental Biology and Medicine, vol. 239, no. 4, pp. 465–476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. A. H. Boulares, A. G. Yakovlev, V. Ivanova et al., “Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells,” Journal of Biological Chemistry, vol. 274, no. 33, pp. 22932–22940, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Ahmad, S. Gupta, M. M. Husain, K. M. Heiskanen, and H. Mukhtar, “Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells,” Clinical Cancer Research, vol. 6, no. 4, pp. 1524–1528, 2000. View at Google Scholar · View at Scopus
  32. S. J. Lee, H. Ahn, K. W. Nam, K. H. Kim, and W. Mar, “Effects of rutaecarpine on hydrogen peroxide-induced apoptosis in murine hepa-1c1c7 cells,” Biomolecules & Therapeutics, vol. 20, no. 5, pp. 487–491, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. E.-S. A. Arafa, Q. Zhu, Z. I. Shah et al., “Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells,” Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis, vol. 706, no. 1-2, pp. 28–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Viglietto, M. L. Motti, P. Bruni et al., “Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27kip1 by PKB/Akt-mediated phosphorylation in breast cancer,” Nature Medicine, vol. 8, no. 10, pp. 1136–1144, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. B. D. Clarkson and J. H. Burchenal, “Preliminary screening of antineoplastic drugs,” Progress in Clinical Cancer, vol. 1, pp. 625–629, 1965. View at Google Scholar